Loading…
S. 4332119th CongressIn committeeLatest action Apr 16, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
S 4332 requires HHS to publicly post expiration dates for biological drug protections within set deadlines so competitors know when they can enter the market.
50-second read · 4 questions answered below
This bill requires the Department of Health and Human Services to publicly post deadlines showing when biological drugs lose their legal protection from cheaper competitor versions called biosimilars. For newly approved drugs, that information must be posted within 30 days of when the expiration date can first be known. For drugs already on the market when the law takes effect, the agency has either 30 days from when the date becomes known or up to 2 years to post it.
This bill affects companies that make biosimilars and companies that make the original biological drugs. Patients and insurers are also affected once those protection periods expire and lower-cost competition becomes possible.
Right now, exclusivity expiration dates are not always listed publicly in a timely way, which can make it harder for biosimilar makers to know when they are legally allowed to enter the market. This bill sets clear posting deadlines to make that information available sooner.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a Senate committee is reviewing it. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.